Eli Lilly Rates High in Growth Model Analysis

Eli Lilly shines in a recent growth stock report, achieving an 88% rating in the P/B Growth Investor model. This high score reflects strong fundamentals, likely positively influencing future stock prices.

Date: 28-02-2025

AI Rating: 7

Eli Lilly and Company (LLY) has received a commendable rating of 88% from a growth investment strategy, specifically the P/B Growth Investor model. This rating is significant as it indicates strong underlying fundamentals and favorable stock valuation. The report suggests that a score of 80% or above usually signals interest in the stock, while a score exceeding 90% indicates strong enthusiasm.

Several key metrics contribute to this positive evaluation:

Book/Market Ratio: PASS
Return on Assets: PASS
Cash Flow from Operations to Assets: PASS
Cash Flow from Operations to Assets vs. Return on Assets: PASS
Return on Assets Variance: PASS
Sales Variance: PASS
Advertising to Assets: PASS
Capital Expenditures to Assets: PASS

These pass results indicate that LLY is performing well across various fundamental aspects. However, it is important to note that it fails in one critical area:

Research and Development to Assets: FAIL

This failure could impact investors' perceptions of the company's long-term innovation potential, which is essential in the biotechnology and drugs industry. Despite this, the substantial number of passes in key metrics supports a positive outlook for the stock.

Stocks: LLY